Premium
Immune dysfunctions: New targets of drug discovery for alzheimerapos;s disease and other cognitive disorders
Author(s) -
Lal Harbans,
Forster Michael J.,
Retz Konrad C.,
Reisberg Barry
Publication year - 1988
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430150202
Subject(s) - disease , neuroscience , immune system , cognition , drug discovery , autoimmunity , medicine , psychology , immunology , bioinformatics , biology , pathology
The development of treatments applicable to Alzheimerapos;s disease and other age‐associated dementias represents a serious challenge to biomedical research. It is suggested that advances in the understanding of basic etiologic mechanisms in these disorders would provide the most direct avenues to discovery of preventive and arrestive treatments. An overview of research relating to the potential involvement of immune dysfunctions in the etiology of Alzheimerapos;s and other central nervous system (CNS) diseases is reviewed as this was presented and discussed in a recent satellite symposium, “Autoimmunity: Its Role in Alzheimerapos;s Disease and Other Behavioral Dysfunctions,” held at the 17th Annual Meeting of The Society for Neuroscience. It is predicted that some future research may focus on immunological dysfunctions as targets for the discovery and development of drugs for treatment of Alzheimerapos;s dieseas and other cognitive disorders.